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Abstract
Background: To characterize the existing national and multi-national registries and cohort studies in juvenile
idiopathic arthritis (JIA) and identify differences as well as areas of potential future collaboration.
Methods: We surveyed investigators from North America, Europe, and Australia about existing JIA cohort studies
and registries. We excluded cross-sectional studies. We captured information about study design, duration, location,
inclusion criteria, data elements and collection methods.
Results: We received survey results from 18 studies, including 11 national and 7 multi-national studies representing 37
countries in total. Study designs included inception cohorts, prevalent disease cohorts, and new treatment cohorts
(several of which contribute to pharmacosurveillance activities). Despite numerous differences, the data elements
collected across the studies was quite similar, with most studies collecting at least 5 of the 6 American College of
Rheumatology core set variables and the data needed to calculate the 3-variable clinical juvenile disease activity score.
Most studies were collecting medication initiation and discontinuation dates and were attempting to capture serious
adverse events.
Conclusion: There is a wide-range of large, ongoing JIA registries and cohort studies around the world. Our
survey results indicate significant potential for future collaborative work using data from different studies and
both combined and comparative analyses.
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Background
Juvenile idiopathic arthritis (JIA), a heterogeneous col-
lection of inflammatory arthritides, is the most common
rheumatic condition of childhood [1]. Despite this, our
understanding of the long-term outcomes for many chil-
dren with this condition, in terms of disease status,
functional limitation, need for long-term immunosup-
pression as well as the development of comorbidities,
remains relatively limited. Similarly, we have an incom-
plete understanding of the potential adverse effects of
new therapeutic agents, especially effects that are rare or
have a long latency period.
The epidemiological study of JIA is challenging.
Compared to the 1% prevalence of rheumatoid arth-
ritis (RA) in adults, JIA is rare. The approximate
worldwide yearly incidence is 8 per 100,000 children
and most prevalence estimates range from 15 to 150
per 100,000 depending on geographic region and
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study methodology [2]. In contrast to the categorization
of the arthritis counterparts in adulthood, JIA encom-
passes a wide range of inflammatory arthritides, from self-
limited oligoarthritis to severe, persistent polyarthritis,
and it also includes psoriatic arthritis, spondyloarthritis,
and systemic arthritis (an autoinflammatory condition).
Results from long-term follow-up studies of JIA may not
be broadly generalizable; they may exclude children with
milder forms of disease who are discharged from rhe-
umatology care, and they may include too few children to
adequately study the less common disease phenotypes.
The long-term study of childhood-onset diseases is
complicated when patients transition to the adult
healthcare setting, making the capture of health out-
come data challenging. However, patients and parents
identify long-term outcomes, such as physical ability
in adulthood, successful schooling and employment,
and the consequences of long-term exposure to im-
munosuppression in childhood, as some of their key
priorities for research [3, 4].
With the advent of biological therapies and their in-
creasing use, reliable outcome data in JIA has become
even more crucial. Little is known about the back-
ground rates of serious outcomes, such as infections
and malignancies, making it difficult to interpret the
safety of new medications. Extrapolation from studies
of these drugs in adults with RA has limited accuracy
because most children with JIA do not have RA (only
approximately 5% have rheumatoid factor positive
polyarthritis) and children have far fewer serious
comorbid conditions compared to adults. Exposure to
immune modulating drugs in developing immune sys-
tems may also result in different longer-term adverse
health outcomes compared to more mature immune
systems.
Given the rarity of JIA and the now frequent use of
potentially high risk treatments in the absence of ro-
bust, large, long-term safety studies, the capture of data
in longitudinal cohorts is essential. Appropriately com-
bining data from various cohorts enables detection of
rare adverse events and more accurate assessment of
disease outcomes. Comparing data from different co-
untries may provide information about genotypic
variations in disease and geographic variation in envir-
onmental risk factors. It may also allow for compari-
sons of treatment differences that result largely from
local availability of therapeutic agents rather than dif-
ferences in disease characteristics.
The purpose of this study was to survey the inter-
national landscape of prospective longitudinal registries
and cohort studies in JIA to assess the breadth and
depth of data being collected. This information will
inform future international collaborative work in JIA,
including data harmonization for future studies.
Methods
A list of existing JIA registries and cohort studies was
compiled through known contacts of the authors, ongoing
collaborations, and a review of the recent literature. This
included studies conducted in the United States of Amer-
ica (USA), Canada, United Kingdom (UK), Germany, the
Netherlands, Sweden, Norway, Portugal, and Australia, as
well as some multi-national studies. A survey developed
in Microsoft Excel (2010) was emailed to the principal in-
vestigators of each registry or cohort. The survey also
asked for additional registries or cohorts known to the re-
spondent. Surveys were completed between October and
December 2014. Owing to delays in manuscript prepar-
ation and in an effort to provide the most recent informa-
tion possible, all respondents were given the opportunity
to revise their responses in March 2016.
The survey captured details about each registry or co-
hort study, including study design, study duration, loca-
tion, inclusion criteria and number of participants, and
data elements and collection method. Cross-sectional
studies, defined as those with less than 12 months of
planned follow-up per participant, were excluded.
Results
In total, 20 investigators were contacted, and the replies
described 20 studies. Two identified studies were not in-
cluded (CLARITY from Australia [5] and EPOCA from
PRINTO [6]) due to cross-sectional design. The
remaining 18 studies contain more than 60,000 patients
with JIA (Table 1). These studies include 11 national and
7 multi-national cohorts (covering more than 37 coun-
tries in total), with data spanning from 1993 until 2016
onwards. These included 5 JIA inception cohorts
(recruiting exclusively from disease onset), 6 prevalent
disease cohorts (without strict requirements about dis-
ease duration or treatment), and 7 treatment cohorts
(restricted to children starting certain anti-rheumatic
therapies, such as biologics). Data from treatment co-
horts were often part of pharmacosurveillance regulatory
requirements. A majority of studies had been established
within the past 15 years. Despite the long duration of
some studies, the number of total subjects recruited to
each study remained relatively low, with few national
studies exceeding 1500 children.
Most studies are still recruiting and continuing to follow-
up children previously recruited. The planned length of
follow-up varied across studies and was generally
dependent on the amount or nature of funding available
(data not shown). A majority of studies were based in a
single country or a small number of countries within a geo-
graphic area. One noted exception is the large multi-
national Pharmacovigilance in Juvenile Idiopathic Arthritis
Patients (Pharmachild) collaboration,which was initiated
with a European Union grant from the Framework
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Programme 7, managed by the Pediatric Rheumatology
International Trials Organization (PRINTO), and has re-
cruited children from 28 countries.
The vast majority of studies recruited children,
although 2 studies (The British Society for Rheumatol-
ogy Biologics Register (BSRBR) [7] and The German
Juvenile Arthritis - Methotrexate/Biologics Long-term
Observation Study (JUMBO) [8], specifically recruit
adult patients with JIA receiving biologic therapies. Most
studies stop follow-up after children leave paediatric
care; however, there are several exceptions. The Portu-
guese register, Reuma.pt, is built into routine care and
continues to capture data from patients into adulthood
[9]. JUMBO is a follow-on study that links adults who
were followed in the German BiKeR registry [10, 11] as
children. Similarly, the UK BSPAR [12] and BCRD regis-
ters [13] continue to capture outcome data about young
adults from their adult care providers. The CARRA
Registry follows young adults after transition of care via
a structured survey conducted by a telephone call center
[14]. Pharmachild has the option for adult rheumatology
centers to submit data and plans to collect data directly
from young adults after transition of care by use of the
JAMAR questionnaire [15].
Despite differences in geographic location, time since
study inception, and study designs, the data elements
collected across studies appears to be quite similar
(Table 2). All studies but one capture the International
League of Associations for Rheumatology (ILAR) cat-
egory of JIA [1]. More than two-thirds of studies capture
the full American College of Rheumatology JIA core
outcome set (count of joints with active arthritis,
count of joints with limited range of motion, phys-
ician global assessment of overall disease activity,
patient/parent global assessment of overall well-being,
functional ability (Childhood Health Assessment
Questionnaire (CHAQ) score), inflammatory markers)
[16]. Nearly all of the remaining studies capture 5 of
the ACR core outcome variables. Fifteen studies
(83%) collect the data needed to calculate the 10 or
71-joint Juvenile Arthritis Disease Activity Score
(JADAS-10 or JADAS-71) [17], and 16 can calculate
the 3-variable clinical JADAS (cJADAS) which omits
inflammatory markers [18]. All studies enrolling chil-
dren captured data on the presence or absence of
uveitis. Most studies (83%) captured medication start
and stop dates. Fourteen studies (78%) captured the
occurrence of serious adverse events (e.g., requiring
hospitalisation), but only 28% had the ability to cap-
ture these data additionally through external data
sources (the majority based in the UK). Seven regis-
tries were working with industry to perform pharma-
cosurveillance studies and included monitoring of
data and adjudication of adverse event reports.
Biosample collection was performed in most of the
registries. Nine registries had relatively systematic collec-
tion, and 7 had more limited collection on a subset of
patients. Serum, plasma, and whole blood/DNA were
the most commonly collected samples. Synovial fluid
was collected less frequently.
Discussion
This is the first report to bring together information
about the numerous existing JIA registries and longitu-
dinal cohort studies, highlighting a wealth of JIA out-
come data being collected around the world. Many
important questions surround the etiology, pathogenesis,
optimal management, and long-term outcomes of JIA.
No single registry can answer all questions. Registries
must have a clearly defined purpose that determines the
process of data collection and the specific data items
collected.
Three primary patient enrolment strategies are being
used: diagnosis inception cohorts, prevalence or con-
venience cohorts, and treatment initiation cohorts.
Although all studies aim to assess disease outcomes over
time, inception cohorts better identify predictors of
short and long-term outcomes (e.g. social, clinical, psy-
chological, laboratory and genetic) [19], whereas treat-
ment initiation cohorts are superior to evaluate
treatment effectiveness and safety. Of course, with suffi-
cient patient enrolment and procedures to collect data
at times when medications are newly started, treatment
cohort studies can be performed within a subset of pa-
tients from any registry.
Whilst one study started collecting data as early as
1993, most initiated recruitment following the introduc-
tion of biologic therapies for JIA around 2000. This was
likely a direct result of increased monitoring and safety
concerns among investigators, sponsors, and patients
with JIA. The relatively recent increase of JIA cohort
studies coincided with a movement in the late 1990’s to
classify children with chronic arthritis into homogenous
groups to facilitate research using the ILAR classification
[1], and this is reflected by all paediatric studies classify-
ing children according to this system. Most studies con-
tinue to actively recruit and follow previously recruited
patients.
Unfortunately, many studies cease to follow patients
after they transition into adult care. The transition of
care period presents many challenges. Patients not only
change clinicians and often their place of residence, but
also may change medical systems and third-party payers.
The most relevant outcome measures may also change,
such as a change from active and limited joint counts in
paediatric clinics to counts of tender and swollen joints
in adult clinics, or change from JADAS to RA disease
activity measures (e.g., DAS28).
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With the majority of JIA studies initiating in the
2000’s only preliminary results on adult-aged patients
are currently available. Two studies specifically assess ef-
fectiveness and safety of biologics in adult patients with
JIA. The German JuMBO study has published outcome
data of 346 children (median age 21 years) who had re-
ceived the biologic etanercept in childhood [8]. The UK
BSRBR study has published data on outcomes of 225
adults with JIA who started a biological therapy in child-
hood [7]. In previous studies, outcomes of adults with
JIA have been assessed cross-sectionally [20–22], retro-
spectively [23], or by identifying adult patients diagnosed
as children from medical records [24–27]. These studies
reported approximately 40 to 60% of children with JIA
continue to have some level of active disease in adult-
hood [22, 24, 25, 27–29]. Given the relative rarity of JIA
and that not all children continue to have active disease
in adulthood, it will be important for registries to share
their experiences to develop robust methods to track
children through adulthood. Because few patients en-
rolled in the current studies have reached adulthood,
this may be an opportunity now to align the data to be
collected in the future across studies.
The studies included in our survey do not reflect the
entirety of long-term outcomes studies in JIA. Several
recent studies have used administrative data to investi-
gate the risk of rare outcomes in JIA, such as malignancy
or serious infection [30–32]. Administrative data sources
provide readily available data and often very large sample
sizes, but provide scant clinical data compared to clinical
cohorts. Accordingly, administrative data are typically
most useful for studies of adverse effects of medications,
but are less useful for studies of medication effectiveness
or long-term outcomes in JIA.
Although there were many differences among the
studies, there was significant overlap in the data being
collected. This may allow for the determination of a
minimal data set that all existing and future prospective
observational studies could collect, enabling nearly iden-
tical analysis plans to be conducted across all data
sources.
Our survey was able to summarize the extent of data
items captured, but did not collect estimates of the
amount of missing data for each variable. Missing data
are a common problem in observational research due to
clinic non-attendance by patients, variable clinical need
for investigation (e.g. inflammatory marker and other
blood testing), and failure to report adverse events in
busy outpatient clinics, among others. This can result in
biases that require careful consideration of how to han-
dle missing data and missing patients. This issue is com-
pounded further in JIA due to the heterogeneity of
disease, with many children who are well being dis-
charged from secondary care and therefore no longer
contributing to longer term outcome studies. Also, our
survey did not enquire in detail about the timing of data
capture, particularly in relation to disease onset or start
of therapies.
In order to understand the risk of rare outcomes, large
sample sizes and long term follow up are needed. Com-
bining data from multiple studies increases statistical
power, but must be done carefully. It is reassuring that
there is significant commonality on the data items
captured across studies, which may permit the creation
of a common data model to pool data. However, differ-
ing methods of outcome ascertainment (e.g., assessing
adverse events by patient report, physician report, or
through an external data source) may produce important
differences in results. It will also be important to ensure
that no patients are double-counted if they have been
simultaneously enrolled in more than one registry effort;
this is likely currently best addressed at the individual
clinical site level, but assignment of a universal identifi-
cation number allowing patients to contribute to various
different registries over time (e.g., in response to changes
in age or geographic location) would have potential add-
itional benefits.
This survey did not account for the differences in
health care systems, clinical expertise in JIA, or funding
for arthritis medications around the world. Because pa-
tients are enrolled from pediatric rheumatology centers,
differences in health care systems may influence enrol-
ment into JIA registries through physician referral bias.
Differential access to biologics likely results in substan-
tial differences in disease duration and severity at the
time of starting treatment. Given the differences in
patient enrolment and data collection techniques, as well
as geographical differences in treatment approaches,
genetic background of the patients, and varying inci-
dences of comorbid conditions and endemic pathogens
(such as tuberculosis), simple pooling of data may not be
the most appropriate approach to evaluate drug safety or
effectiveness. In addition, there may be restrictions on
the sharing of data, depending on the ethical approval
and patient consent obtained in each study. Overcoming
these hurdles to facilitate collaborative research in JIA
will be challenging and will require an international
effort involving multiple stakeholders. Within the JIA
research community, initial steps have been taken to
begin to address these obstacles [33].
Sophisticated methods for combining data should be
explored, such as nested case-control studies or meta-
analyses of individual register data analysis. These
approaches were adopted by the EULAR Registers and
Observational Drug Studies (RODS) Working Group to
explore the risk of malignant melanoma associated with
TNFi therapies in patients with RA across Europe [34].
Methodological approaches that consider the individual
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data source will likely provide more accurate results and
new insights about confounders and effect modifiers of
outcome. Despite the significant resources required, these
analyses would be a unique opportunity to answer critical
questions about JIA and should be undertaken.
Conclusions
This study identified a wide range of ongoing JIA cohort
studies and registries around the world. Many of the
challenges in the long-term study of childhood-onset
diseases were highlighted. Nevertheless, the results indi-
cate significant potential for future collaborative work
using both combined and comparative analyses of data
from different studies. New approaches to maximise data
capture beyond childhood will be crucial to answer
important questions about long-term outcomes.
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